Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists

summary

Knowledge on the natural history of mesenteric vein thrombosis (MVT) and of the efficacy and safety of long-term oral anticoagulant therapy (OAT) in this setting is based on small uncontrolled series of patients with a limited follow-up. It was the aim of the study to assess the natural history of MVT in a cohort of patients treated with OAT. The charts of all MVT patients currently attending or who have attended four anticoagulation clinics were reviewed. Information on risk factors, treatment, recurrence, major bleeding and mortality was collected. Seventyseven patients (mean age 49.2 years; 45 males) were included with a median follow-up of 36 months (range 2–204 months). Forty-six patients were treated with long-term OAT. Seven patients had venous thromboembolism (VTE) recurrence (5 splanchnic vein thromboses and two pulmonary emboli) for an incidence rate of 23.4 events /1,000 year patients. In two patients recurrentVTE occurred during OAT, for an incidence rate of 10.5 events /1,000 year patient. Five patients had VTE recurrence when OAT was suspened for an incidence rate of 45.9 events /1,000 year patient. Two patients (2.6%) had a major bleeding event. 97.3% of patients were alive at one year, and seven patients (9.1%) died during follow up. In conclusion, patients with MTV seem to have a low risk of recurrentVTE while receiving OAT. This risk appears increased after treatment is stopped.

Keywords

Mesenteric vein thrombosis - oral anticoagulant

• References

• 1 Grendell JH, Ockner RK. Mesenteric venous thrombosis. Gastroenterology 1982; 82: 358-372.
• 2 Kumar S, Sarr MG, Kamath PS. Mesenteric venous thrombosis. N Engl J Med 2001; 345: 1683-1688.
• 3 Brunaud L, Antunes L, Collinet-Adler S. et al. Acute mesenteric venous thrombosis: case for nonoperative management. J Vasc Surg 2001; 34: 673-679.
• 4 Morasch MD, Ebaugh JL, Chiou AC. et al. Mesenteric venous thrombosis: a changing clinical entity. J Vasc Surg 2001; 34: 680-684.
• 5 Grisham A, Lohr J, Guenther JM. et al. Deciphering mesenteric venous thrombosis: imaging and treatment. Vasc Endovascular Surg 2005; 39: 473-479.
• 6 Condat B, Pessione F, Denninger HM. et al. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000; 32: 466-470.
• 7 Hedayati N, Riha GM, Kougias P. et al. Prognostic factors and treatment outcome in mesenteric vein thrombosis. Vasc Endovascular Surg 2008; 42: 217-224.
• 8 Abdu RA, Zakhour BJ, Dallis DJ. Mesenteric venous thrombosis--1911 to 1984. Surgery 1987; 101: 383-388.
• 9 Joh JH, Kim DI. Mesenteric and portal vein thrombosis: treted with early initiation of Anticoagulation. Eur J Vasc Endovasc Surg 2005; 29: 204-208.
• 10 Colaizzo D, Amitrano L, Tiscia GL. et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007; 05: 55-61.
• 11 Agnelli G, Prandoni P, Santamaria MG. et al. Warfarin Optimal Duration Italian Trial Investigators Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001; 345: 165-169.
• 12 Agnelli G, Prandoni P, Becattini C. et al. Warfarin Optimal Duration Italian Trial Investigators Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003; 139: 19-25.
• 13 Austin SK, Lambert JR. The JAK2(V617F) mutation and thrombosis. Br J Haematol 2008; 143: 307-320.